Suppr超能文献

冠状动脉内硝普钠与静脉内腺苷评估血流储备分数的疗效和安全性比较。

Comparison of efficacy and safety of intracoronary sodium nitroprusside and intravenous adenosine for assessing fractional flow reserve.

机构信息

Department of Medicine, New Jersey Medical School, University Hospital, Newark, NJ, USA.

出版信息

Catheter Cardiovasc Interv. 2013 Feb;81(3):540-4. doi: 10.1002/ccd.24652. Epub 2012 Oct 15.

Abstract

OBJECTIVES

The purpose of this study was to compare the efficacy and safety of intracoronary (IC) nitroprusside and intravenous adenosine (IVA) for assessing fractional flow reserve (FFR).

BACKGROUND

IV infusion of adenosine is a standard method to achieve a coronary hyperemia for FFR measurement. However, adenosine is expensive, causes multiple side effects, and is contraindicated in patients with reactive airway disease. Sodium nitroprusside (NTP) is a strong coronary vasodilator but its efficacy and safety for assessing FFR is not well established.

METHODS

We compared FFR response and side effects profile of IC NTP and IVA. Bolus of NTP at a dose of 100 μg and IVA (140 μg/kg/min) were used to achieve coronary hyperemia.

RESULTS

We evaluated 75 lesions in 53 patients (60% male) mean age 61.6 ± 13.9 years. Mean FFR after NTP was similar to FFR after adenosine (0.836 ± 0.107 vs. 0.856 ± 0.106; P = 0.26; r = 0.91, P < 0.001). NTP induced maximal stable hyperemia within 10 sec (mean: 6.4 ± 1) which lasted consistently between 38 and 60 sec (mean 51 ± 7.5). NTP caused significant (14%), but asymptomatic decrease in mean blood pressure which returned to baseline within 60 sec. Adenosine caused shortness of breath in 26%, headache and flushing in 19%, and transient second degree heart block in 6% of patients. No adverse symptoms were reported after NTP.

CONCLUSIONS

IC NTP is as effective as IVA for measuring FFR. NTP is better tolerated by patients. Since NTP is inexpensive, readily available, well tolerated, and safe, it may be a better choice for FFR assessment.

摘要

目的

本研究旨在比较冠状动脉内(IC)硝普钠和静脉内腺苷(IVA)在评估血流储备分数(FFR)方面的疗效和安全性。

背景

静脉内输注腺苷是一种用于 FFR 测量的标准方法,可实现冠状动脉充血。然而,腺苷价格昂贵,会引起多种副作用,并且在患有反应性气道疾病的患者中禁忌使用。硝普钠(NTP)是一种强效冠状动脉扩张剂,但它在评估 FFR 方面的疗效和安全性尚未得到充分确立。

方法

我们比较了 IC NTP 和 IVA 的 FFR 反应和副作用特征。使用 100μg 的 NTP 剂量和 140μg/kg/min 的 IVA 推注来实现冠状动脉充血。

结果

我们评估了 53 名患者(60%为男性)的 75 个病变,平均年龄为 61.6±13.9 岁。NTP 后的平均 FFR 与腺苷后的 FFR 相似(0.836±0.107 比 0.856±0.106;P=0.26;r=0.91,P<0.001)。NTP 在 10 秒内诱导出最大稳定充血(平均:6.4±1),并在 38 到 60 秒之间持续稳定(平均 51±7.5)。NTP 导致平均血压显著(14%)但无症状下降,血压在 60 秒内恢复至基线。腺苷引起 26%的患者呼吸急促、19%的患者头痛和潮红、6%的患者短暂出现二度房室传导阻滞。NTP 后无不良反应报告。

结论

IC NTP 与 IVA 一样有效用于测量 FFR。NTP 更受患者耐受。由于 NTP 价格低廉、易于获得、耐受性良好且安全,因此它可能是评估 FFR 的更好选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验